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Abstract 
The serum copper protein ceruloplasmin, though sometimes considered an antioxidant, can promote lipoprotein oxidation in vitro 
under certain conditions. However, an inflammation-induced, twoweek elevation of rat serum ceruloplasmin levels did not render low 
plus very low density lipoproteins more prone to oxidation in vitro. Thus, high ceruloplasmin levels in vivo are not necessarily associated 
with high lipoprotein oxidation rates. 
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Ceruloplasmin is a multifunctional protein which con- 
tains most of the copper in serum [1]. This protein is 
thought o possess antioxidant functions which could be 
beneficial in resisting disease [2]. In contrast o this con- 
cept, high serum ceruloplasmin levels have been specu- 
lated to foster atherosclerosis [3-8]. This notion is based 
on three lines of reasoning. First, some studies have corre- 
lated above normal ceruloplasmin levels with cardio- 
vascular disease (reviewed in [3]). For example, an epi- 
demiology study in Finland associated high serum cerulo- 
plasmin levels with high risk of myocardial infarction and 
stroke [8]. Second, lipoprotein oxidation, which is thought 
to lead to atherosclerosis, can be catalyzed by copper [9], a 
component of ceruloplasmin [1]. Third, under some cir- 
cumstances, ceruloplasmin itself can promote lipoprotein 
oxidation in vitro [3-7]. 
The present study examined whether an inflammation- 
stimulated increase in rat serum ceruloplasmin altered the 
susceptibility of lipoproteins to oxidation. Such susceptibil- 
ity is most commonly examined by measuring low density 
lipoprotein (LDL) oxidation by copper in vitro [9]. It is 
assumed that oxidation lag time and propagation rate in 
vitro reflect the vulnerability of LDL to oxidation in vivo 
[9]. This study used this general approach, except hat a 
combination of LDL and very low density lipoproteins 
(VLDL) were examined. This was done because rat plasma 
contains relatively small concentrations of LDL [10]. Since 
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both LDL and VLDL are subject o oxidation [11], it is 
technically easier to use the VLDL/LDL combination for 
rat oxidation studies. This has been done for other rat 
studies on lipoprotein oxidation (i.e. [12)]. An added ad- 
vantage to the VLDL/LDL combination approach is the 
elimination of long lipoprotein preparation times and dialy- 
sis steps generally used to prepare LDL. Conceivably, both 
could affect oxidation results [11,13]. 
Male, Sprague Dawley rats, weighing 250 to 300 g 
were obtained from Harlan Sprague Dawley (Indianapolis, 
IN) and fed Teklad 22/5 Rodent Diet (Madison, WI) ad 
libitum. Ceruloplasmin levels were elevated, when applica- 
ble, by inflammation produced by turpentine injection (0.1 
ml, im, leg). Serum ceruloplasmin was assessed by its 
enzyme activity using oxidation of p-phenylenediamine 
[14]. One unit was arbitrarily defined as the absorbance 
change at 540 nm/1.5 min. In copper adequate rats, 
turpentine-stimulated inflammation raises ceruloplasmin 
levels to the same degree for both enzyme activity and 
immunoreactive protein [15]. 
Blood, collected by cardiac puncture, was drawn into 
EDTA-containing vacuum tubes. Plasma was separated by 
centrifugation (1500 × g, 15 min). LDL + LDL was iso- 
lated with a precipitation procedure [11]. VLDL + LDL 
oxidation was measured after stimulation by copper sulfate 
(50 mM), and monitored by conjugated iene formation at 
37°C as described by Esterbauer [16]. The cholesterol 
concentration of the EDTA-free, non-HDL fraction was 
adjusted to 75 /xg/ml for the oxidation measurements 
(Cholesterol Kit from Sigma Chemical Co., St Louis, 
MO). The lag phase was determined by drawing a line 
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Fig. 1. Inflammation-induced increases in serum ceruloplasmin. Each 
time point represents mean values for 4 rats _+SD. Inflammation was 
initiated by turpentine injection and boosted with a second injection for 
the 12- and 14-day time points (see text for details). Ceruloplasmin values 
for each time point beyond ay 0 was significantly different from day 0 
values (unpaired Student's t-test, P < 0.001). 
tangent to the propagation phase of the curve and extrapo- 
lating this line through the horizontal axis [16]. The inter- 
val between copper addition and the intersection point on 
this axis was defined as the lag time. Propagation rate was 
based on a molar extinction coefficient for conjugated 
dienes [16]. 
Inflammation elevated ceruloplasmin above normal val- 
ues for the two weeks examined (Fig. 1). Increased cerulo- 
plasmin levels were not associated with above normal 
susceptibility of VLDL + LDL to oxidation in vitro (Table 
1). Oxidation was measured both by lag time and propaga- 
tion rate. 
Humans with lipoproteins that oxidize quickly in vitro 
are thought o be vulnerable to atherosclerosis [9]. Cerulo- 
plasmin has been speculated to participate in lipoprotein 
oxidation and atherosclerosis [3-8]. Therefore, it might be 
predicted that high ceruloplasmin concentrations in viva 
would lead to lipoproteins with high vulnerability to oxida- 
tion. On the other hand, low ceruloplasmin concentrations 
might do the opposite. This study found the first prediction 
Table 1 
VLDL + LDL oxidation and ceruloplasmin values in rats with and with- 
out inflammation 
VLDL + LDL oxidation 
Lag time Propagation 
(min) rate (pmol/ 
min per mg 
cholesterol) 
Ceruloplasmin (U/ l)  
Control 58 + 8 2.3 + 0.9 69 + 37 
Inflammation 53+ 17 1.8+0.4 201 +37 a 
Values are the means+ SD, with n = 9 (control) or 7 (inflammation). 
Rats with inflammation were treated similarly to the rats designated as 14 
days in Fig. 1. 
" Significantly different from control (unpaired Student's t-test). 
to be false when rat serum ceruloplasmin values were 
elevated by leg inflammation. The latter prediction has 
also been shown to be false, at least when copper defi- 
ciency in rats produces low ceruloplasmin levels [12]. In 
this case, VLDL + LDL shows high susceptibility to oxi- 
dation. Possibly, in copper deficiency, other factors, such 
as low extracellular superoxide dismutase activities [17], 
dominate over any effects of low ceruloplasmin. Still, this 
is not certain. What is certain is that in two controlled 
studies in rats, ceruloplasmin values have not correlated 
directly with lipoprotein proneness to oxidation. 
One potential imitation of the present study was the 
time period allowed for high ceruloplasmin concentrations. 
It could be argued that two weeks is insufficient o alter 
lipoprotein oxidation tendencies. However, our laboratory 
has shown that two weeks of a treatment in rats can 
produce a dramatic rise in VLDL + LDL proneness to 
oxidation [18]. A moderate zinc deficiency gave very short 
VLDL + LDL oxidation lag times and high propagation 
rates. Similarly, in human studies, 10 days to 2 weeks of 
various treatments have been sufficient o produce changes 
in lipoprotein oxidation tendencies (i.e. [19,20]). 
Fox's group [3] has noted that some proteins, such as 
albumin, inhibit ceruloplasmin-induced oxidation of LDL 
in vitro. In the present study, ceruloplasmin's prooxidant 
actions might have been negated in viva by other plasma 
proteins. However, it is also possible that native cerulo- 
plasmin does not actually have any prooxidant action 
toward lipoproteins, either in viva or in vitro. Two reports 
of prooxidant actions of ceruloplasmin obtain the action 
only after exposing this protein to either low pH or perox- 
ynitrite [6,7]. These harsh conditions likely loosen some of 
the coppers on ceruloplasmin. On the other hand, Fox's 
laboratory [3,4] reports that a native ceruloplasmin, con- 
taining 7 copper atoms per molecule, exerts prooxidant 
actions in vitro. The prooxidant actions seem due to one 
loose copper which can be removed by Chelex-100 treat- 
ment. However, many ceruloplasmin preparations are re- 
ported to contain only 6 tightly bound coppers (i.e., [21- 
23]). In fact, any loosely bound copper is typically consid- 
ered as exogenous to the actual ceruloplasmin molecule 
[22,23]. In serum, any binding of this exogenous copper is 
likely short lived since albumin can bind such copper very 
effectively [22]. This could explain why albumin inhibits 
the reported oxidant action of ceruloplasmin toward LDL 
[31. 
If ceruloplasmin has no prooxidant effects in viva, or if 
those effects are negated by other factors, then a question 
must be raised. Why are high ceruloplasmin values in 
humans sometimes correlated with high risk of cardio- 
vascular disease (i.e., [3,8])? It is possible that the high 
ceruloplasmin values are an effect, not a cause of the high 
risk. High risk subjects likely experience physiologic stress, 
and many types of physiologic stress tend to raise cerulo- 
plasmin levels [1]. 
In summary, this study does not support he hypothesis 
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that high ceruloplasmin levels lead to high rates of lipopro- 
tein oxidation, a possible factor in atherosclerosis. 
References 
[1] Cousins, R.J. (1985) Physiol. Rev. 65, 238-309. 
[2] Halliwell, B. (1990) Arch. Biochem. Biophys. 280, 1-8. 
[3] Fox, P.L., Mukhopadhyay, C. and Ehrenwald, E. (1995) Life Sci. 
56, 1749-1758. 
[4] Ehrenwald, E., Chisolm, G.M. and Fox, P.L. (1994) J. Clin. Invest. 
93, 1493-1501. 
[5] Mukhopadhyay, C.K., Ehrenwald, E. and Fox, P.L. (1996) J. Biol. 
Chem. 56, 14773-14778. 
[6] Lamb, D.J. and Leake, D.S. (1994) FEBS Lett. 338, 122-126. 
[7] Swain, J.A., Darley-Usmar, V. and Gutteridge, J.M.C. (1994) FEBS 
Lett. 342, 49-52. 
[8] Reunanen, A., Knekt, P. and Aaran, R.-K. (1992) Am. J. Epidemiol. 
136, 1082-1090. 
[9] Esterbauer, H., Wag, G. and Puhl H. (1993) Br. Med. Bull. 49, 
566-576. 
[10] Scaccini, C., Nardini, M., D'Aquino, M., Gentili, V. and Di Felice, 
M. (1992) J. Lipid Res. 33, 627-633. 
[11] Zhang, A., Vertommen, J., Van Gaal, L. and De Leeuw, I. (1994) 
Clin. Chim. Acta 227, 159-173. 
[12] Rayssiguier, Y., Gueux, E. and Bussiere L. (1993) J. Nutr. 123, 
1343-1348. 
[13] Scheek, L.M., Wiseman, S.A., Tijburg, L.B.M. and van Tol, A. 
(1995) Atherosclerosis 117, 139-144. 
[14] Rice, E. (1962) Anal. Biochem. 3, 452-456. 
[15] DiSilvestro, R.A., Barber, E.F., David, E.A. and Cousins, R.J. 
(1988). Biol. Trace Elem. Res. 17, 1-9. 
[16] Esterbauer, H., Striegl, G. and Puhl, H. (1989) Free Rad. Res. 
Commun. 6, 67-75. 
[17] DiSilvestro, R.A. (1988) J. Nutr. 118, 474-479. 
[18] DiSilvestro, R.A. and Blostein-Fujii, A. (1996) Free Rad. Biol. 
Med., in press. 
[19] Rifici, V.A. and Khachadurian, A.K. (1993) J. Am. Coll. Nutr. 12, 
631-637. 
[20] Fuhrman, B., Lavy, A. and Aviram, M. (1995) Am. J. Clin. Nutr. 
61,549-554. 
[21] Calabrese, L.C., Malatesta, F. and Barra, D. (1981) Biochem. J. 199, 
667-673. 
[22] Zgirski, A. and Frieden, E. (1990) J. Inorg. Biochem. 39, 137-148. 
[23] Laurie, S. and Mohammed, E.S. (1980) Coord. Chem. Rev. 33, 
279-312. 
